Sinocare Toekomstige groei

Future criteriumcontroles 3/6

Sinocare zal naar verwachting groeien in winst en omzet met respectievelijk 34.9% en 12.3% per jaar. De winst per aandeel zal naar verwachting groeien met 34.5% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 13.3% zijn.

Belangrijke informatie

34.9%

Groei van de winst

34.5%

Groei van de winst per aandeel

Medical Equipment winstgroei	27.0%
Inkomstengroei	12.3%
Toekomstig rendement op eigen vermogen	13.3%
Dekking van analisten	Good
Laatst bijgewerkt	30 Oct 2024

Recente toekomstige groei-updates

Recent updates

Winst- en omzetgroeiprognoses

SZSE:300298 - Toekomstschattingen van analisten en financiële gegevens uit het verleden (CNY Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	5,577	587	621	789	5
12/31/2025	4,938	460	548	604	6
12/31/2024	4,434	371	313	572	6
9/30/2024	4,206	222	476	729	N/A
6/30/2024	4,184	307	353	711	N/A
3/31/2024	4,190	306	303	657	N/A
12/31/2023	4,059	284	389	735	N/A
9/30/2023	4,137	379	241	578	N/A
6/30/2023	4,110	392	470	755	N/A
3/31/2023	4,215	441	434	760	N/A
1/1/2023	3,952	447	362	682	N/A
9/30/2022	3,463	296	485	803	N/A
6/30/2022	3,081	218	258	610	N/A
3/31/2022	2,478	128	171	475	N/A
1/1/2022	2,361	108	76	480	N/A
9/30/2021	2,235	134	-58	366	N/A
6/30/2021	2,174	147	-22	365	N/A
3/31/2021	2,095	168	28	435	N/A
12/31/2020	2,015	187	229	505	N/A
9/30/2020	2,049	287	324	566	N/A
6/30/2020	1,936	280	245	502	N/A
3/31/2020	1,831	265	273	517	N/A
12/31/2019	1,778	251	101	523	N/A
9/30/2019	1,651	286	-26	474	N/A
6/30/2019	1,604	272	66	534	N/A
3/31/2019	1,607	276	-72	368	N/A
12/31/2018	1,551	310	77	319	N/A
9/30/2018	1,429	286	-22	116	N/A
6/30/2018	1,301	333	N/A	59	N/A
3/31/2018	1,112	296	N/A	158	N/A
1/1/2018	1,033	258	N/A	244	N/A
9/30/2017	994	206	N/A	270	N/A
6/30/2017	945	156	N/A	272	N/A
3/31/2017	849	116	N/A	223	N/A
12/31/2016	796	115	N/A	203	N/A
9/30/2016	722	138	N/A	231	N/A
6/30/2016	674	121	N/A	180	N/A
3/31/2016	698	155	N/A	183	N/A
12/31/2015	646	144	N/A	122	N/A
9/30/2015	634	176	N/A	164	N/A
6/30/2015	611	191	N/A	170	N/A
3/31/2015	570	199	N/A	147	N/A
12/31/2014	545	197	N/A	153	N/A
9/30/2014	506	191	N/A	131	N/A
6/30/2014	488	176	N/A	133	N/A
3/31/2014	450	157	N/A	128	N/A
12/31/2013	449	165	N/A	114	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei 300298 ( 34.9% per jaar) ligt boven de spaarquote ( 2.8% ).

Winst versus markt: De winst van 300298 ( 34.9% per jaar) zal naar verwachting sneller groeien dan de CN markt ( 26.3% per jaar).

Hoge groeiwinsten: De winst van 300298 zal naar verwachting de komende 3 jaar aanzienlijk groeien.

Omzet versus markt: De omzet van 300298 ( 12.3% per jaar) zal naar verwachting langzamer groeien dan de markt CN ( 14% per jaar).

Hoge groei-inkomsten: De omzet van 300298 ( 12.3% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen 300298 zal naar verwachting over 3 jaar laag zijn ( 13.3 %).

Sinocare Toekomstige groei

Future criteriumcontroles 3/6

Belangrijke informatie

Recente toekomstige groei-updates

Consensus EPS estimates fall by 11%

Price target decreased by 8.0% to CN¥31.01

Price target decreased by 14% to CN¥33.71

Price target increased to CN¥39.34

Consensus forecasts updated

Price target decreased to CN¥20.73

Recent updates

We Think You Can Look Beyond Sinocare's (SZSE:300298) Lackluster Earnings

Consensus EPS estimates fall by 11%

New minor risk - Profit margin trend

Estimating The Intrinsic Value Of Sinocare Inc. (SZSE:300298)

Investor sentiment deteriorates as stock falls 15%

Sinocare (SZSE:300298) Is Reinvesting At Lower Rates Of Return

New minor risk - Share price stability

Sinocare Inc. to Report Q3, 2024 Results on Oct 24, 2024

Now 21% overvalued after recent price rise

Investor sentiment improves as stock rises 15%

Second quarter 2024 earnings released: EPS: CN¥0.21 (vs CN¥0.19 in 2Q 2023)

Sinocare Inc.'s (SZSE:300298) Price Is Out Of Tune With Earnings

Calculating The Intrinsic Value Of Sinocare Inc. (SZSE:300298)

Sinocare Inc. to Report First Half, 2024 Results on Aug 29, 2024

Sinocare Inc. Announces Dividend Implementation for 2023, Payable on 17 June 2024

Is Sinocare (SZSE:300298) A Risky Investment?

Sinocare's (SZSE:300298) Soft Earnings Don't Show The Whole Picture

Price target decreased by 8.0% to CN¥31.01

Sinocare Inc., Annual General Meeting, May 21, 2024

Sinocare Inc. Proposes Final Dividend for 2023

First quarter 2024 earnings released: EPS: CN¥0.15 (vs CN¥0.12 in 1Q 2023)

Investor sentiment improves as stock rises 16%

Sinocare Inc.'s (SZSE:300298) P/E Is On The Mark

Now 21% undervalued after recent price drop

Here's What To Make Of Sinocare's (SZSE:300298) Decelerating Rates Of Return

Sinocare Inc. to Report Q1, 2024 Results on Apr 26, 2024

Now 21% undervalued after recent price drop

Investor sentiment deteriorates as stock falls 16%

Sinocare Inc. to Report Fiscal Year 2023 Results on Apr 26, 2024

Investor sentiment improves as stock rises 24%

Third quarter 2023 earnings released: EPS: CN¥0.26 (vs CN¥0.28 in 3Q 2022)

Now 20% undervalued

Sinocare Inc. to Report Q3, 2023 Results on Oct 24, 2023

Now 20% undervalued after recent price drop

Price target decreased by 14% to CN¥33.71

Second quarter 2023 earnings released: EPS: CN¥0.19 (vs CN¥0.26 in 2Q 2022)

Sinocare Inc. (SZSE:300298) announces an Equity Buyback for CNY 150 million worth of its shares.

Sinocare Inc. (SZSE:300298) announces an Equity Buyback for CNY 150 million worth of its shares.

Now 21% undervalued after recent price drop

Investor sentiment improves as stock rises 17%

Sinocare Inc. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2022, Payable on 26 May 2023

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Price target increased to CN¥39.34

Sinocare Inc. Approves Board Elections

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: CN¥0.28 (vs CN¥0.14 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.26 (vs CN¥0.13 in 2Q 2021)

Sinocare Inc. Approves Cash Dividend for the Year 2021

Investor sentiment improved over the past week

Consensus forecasts updated

Price target decreased to CN¥20.73

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

High number of new directors

Sinocare Inc., Annual General Meeting, May 13, 2022

Sinocare Inc. Proposes Cash Dividend for 2021

Third quarter 2021 earnings released: EPS CN¥0.14 (vs CN¥0.16 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.13 (vs CN¥0.17 in 2Q 2020)

Price target decreased to CN¥40.66

Consensus forecasts updated

First quarter 2021 earnings released: EPS CN¥0.079 (vs CN¥0.11 in 1Q 2020)

Investor sentiment deteriorated over the past week

New 90-day low: CN¥31.87

Sinocare Inc. to Report Fiscal Year 2020 Results on Apr 17, 2021

New 90-day high: CN¥46.30

Third quarter earnings released

Sinocare Inc. to Report Q3, 2020 Results on Oct 17, 2020

Earnings released

Sinocare Inc. to Report First Half, 2020 Results on Aug 07, 2020

Winst- en omzetgroeiprognoses